Aruna Bio is pioneering advancements in the treatment of neurological diseases through its proprietary neural exosome platform. This innovative technology enables the delivery of therapeutic agents across the blood-brain barrier, a significant challenge in treating central nervous system (CNS) disorders. The company's lead product, AB126, is derived from neural cells and exhibits multiple mechanisms of action, including the reduction of neuro-inflammation, promotion of neuro-protection, and stimulation of neuro-regeneration. These properties position AB126 as a promising candidate for addressing both acute neuro-conditions and chronic neurodegenerative diseases, potentially transforming the lives of millions affected by these conditions.

In addition to AB126, Aruna Bio is committed to expanding its pipeline of neural exosome-based therapies across a wide range of neurological indications. The company is actively exploring new applications for its technology, with plans to regularly introduce additional indications as research progresses. This ambitious approach underscores Aruna Bio's dedication to unlocking new possibilities for patients suffering from neurological diseases, leveraging the unique capabilities of its exosome platform to develop effective treatments.

United States

Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. We are leveraging our proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing our exosomes with small molecules, RNA, oligonucleotides and antibodies.

Aruna Bio

Company Details